Farxiga® (dapagliflozin) tablets
Approval Date: Apr 2026
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure
Janumet® (sitagliptin and metformin hydrochloride) tablets
Approval Date: Dec 2025
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, this approval is for a first-time generic
Kirsty™ (insulin aspart-xjhz) injection
Approval Date: Jul 2025
Indicated to improve glycemic control in patients with diabetes mellitus
Janumet® XR (sitagliptin phosphate and metformin hydrochloride) extended-release tablets
Approval Date: Jun 2025
Indicated as an adjunct to diet and exercise to improve glycemic control for the treatment of type 2 diabetes
Byetta® (exenatide) injection
Approval Date: Nov 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the treatment of type 2 diabetes, in conjunction with diet and exercise
Victoza® (liraglutide) injection
Approval Date: Dec 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the once-daily treatment of type 2 diabetes, in conjunction with diet and exercise
Zituvimet (sitagliptin and metformin hydrochloride) tablets
Approval Date: Nov 2023
Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes
Kombiglyze® XR (saxagliptin and metformin hydrochloride) extended-release tablets
Approval Date: Jul 2023
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate
Onglyza™ (saxagliptin) tablets
Approval Date: Jul 2023
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Tzield® (teplizumab-mzwv) injection
Approval Date: Nov 2022
A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.
Jardiance® (empagliflozin) tablets
Approval Date: Aug 2022
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Synjardy® (empagliflozin and metformin hydrochloride) tablets
Approval Date: Jul 2022
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Mounjaro™ (tirzepatide) injection
Approval Date: May 2022
Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise
Farxiga (dapgliflozin) tablets
Approval Date: Feb 2022
A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.
Rezvoglar (insulin glargine-aglr) injection
Approval Date: Dec 2021
Indicated to improve glycemic control for type 1 and 2 diabetes
